Literature DB >> 7179738

Chromoblastomycosis. A morphological investigation of the host-parasite interaction.

P Walter, Y Garin, D Richard-Lenoble.   

Abstract

Chromoblastomycosis is a distinct cutaneous mycotic infection. Histologically it is characterized by the presence of fungus invariably in the yeast phase and by macrophages in large numbers. The morphology of fungus in both yeast and hyphal phases and its interaction with mononuclear phagocytes were examined using ultrastructural techniques. The major structural difference between the fungus in cutaneous tissue and that from a culture medium was a striking increase in cell wall thickness in the former. In the skin, the organisms were phagocytised by macrophages and enclosed in large membrane limited intracytoplasmic vacuoles. The thick, stratified, electron-dense fungal cell wall was observed in stages of alteration of varying severity. Most common was a granular modification of the outermost layers of the cell wall in contact with the vacuolar content. Fragmentation, splitting and rupture of this and deeper layers was also seen. Several ultrastructural features suggested that cell wall damage resulted from an active host cell digestion. The cell wall changes were in sharp contrast with the usual normal fungal cytoplasmic appearance. Only rare intracellular debris which we supposed to represent dead yeast cells were found. These findings suggested that the yeast responsible for chromoblastomycosis resisted fungicidal activities of cutaneous macrophages which possessed the ultrastructural features of stimulated phagocytes.

Entities:  

Mesh:

Year:  1982        PMID: 7179738     DOI: 10.1007/bf00442390

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histol        ISSN: 0340-1227


  29 in total

1.  Chromomycosis due to Cladosporium trichoides treated with 5-fluorocytosine. A case report.

Authors:  H Nsanzumuhire; D Vollum; A A Poltera
Journal:  Am J Clin Pathol       Date:  1974-02       Impact factor: 2.493

2.  [Chromomycosis. Visceral metastasizing type].

Authors:  Z Itani
Journal:  Dtsch Med Wochenschr       Date:  1970-05-15       Impact factor: 0.628

3.  The pathogenesis of experimental pulmonary aspergillosis. An ultrastructural study of alveolar macrophages after phagocytosis of a flavus spores in vivo.

Authors:  L P Merkow; S M Epstein; H Sidransky; E Verney; M Pardo
Journal:  Am J Pathol       Date:  1971-01       Impact factor: 4.307

4.  Subcutaneous chromoblastomycosis occurring in a patient with systemic lupus erythematosus.

Authors:  G D Cains; J F Krivanek; K Paver
Journal:  Australas J Dermatol       Date:  1977-08       Impact factor: 2.875

5.  Skin test-active substance prepared from culture filtrate of Fonsecaea pedrosoi.

Authors:  T Iwatsu; M Miyaji; H Taguchi; S Okamoto; N Kurita
Journal:  Mycopathologia       Date:  1979-05-31       Impact factor: 2.574

6.  Experimental visceral aspergillosis.

Authors:  H Sidransky; S M Epstein; E Verney; C Horowitz
Journal:  Am J Pathol       Date:  1972-10       Impact factor: 4.307

7.  Cystic chromomycosis of the skin.

Authors:  D Weedon; G Ritchie
Journal:  Pathology       Date:  1979-07       Impact factor: 5.306

8.  Dematiaceous fungal pathogens isolated from nature.

Authors:  D M Dixon; H J Shadomy; S Shadomy
Journal:  Mycopathologia       Date:  1980-03-31       Impact factor: 2.574

9.  Immunotherapy of coccidioidomycosis.

Authors:  A Catanzaro; L Spitler; K M Moser
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

10.  Role of macrophages in resistance of mice to experimental cryptococcosis.

Authors:  D P Monga
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

View more
  8 in total

1.  Relationship between tissue reactions and morphological changes of the fungi in chromoblastomycosis: morphometry and electron microscopy.

Authors:  C Okuda; M Ito; K Oka
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

Review 2.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  The in vitro susceptibility of Fonsecaea pedrosoi to activated macrophages.

Authors:  S Rozental; C S Alviano; W de Souza
Journal:  Mycopathologia       Date:  1994-05       Impact factor: 2.574

4.  The cell-mediated immune reaction in the cutaneous lesion of chromoblastomycosis and their correlation with different clinical forms of the disease.

Authors:  Solange Corrêa Garcia Pires d'Avila; Carla Pagliari; Maria Irma Seixas Duarte
Journal:  Mycopathologia       Date:  2003       Impact factor: 2.574

Review 5.  Hyalohyphomycosis and phaeohyphomycosis: two global disease entities of public health importance.

Authors:  L Ajello
Journal:  Eur J Epidemiol       Date:  1986-12       Impact factor: 8.082

6.  Granulomatous reaction and tissue remodelling in the cutaneous lesion of chromomycosis.

Authors:  P Esterre; S Peyrol; D Sainte-Marie; R Pradinaud; J A Grimaud
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  The Major Chromoblastomycosis Etiologic Agent Fonsecaea pedrosoi Activates the NLRP3 Inflammasome.

Authors:  Raffael Júnio Araújo de Castro; Isaque Medeiros Siqueira; Márcio Sousa Jerônimo; Angelina Maria Moreschi Basso; Paulo Henrique de Holanda Veloso Junior; Kelly Grace Magalhães; Luiza Chaves Leonhardt; Stephan Alberto Machado de Oliveira; Pedro Henrique Bürgel; Aldo Henrique Tavares; Anamélia Lorenzetti Bocca
Journal:  Front Immunol       Date:  2017-11-20       Impact factor: 7.561

Review 8.  Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis.

Authors:  Luiz Felipe Domingues Passero; Italo Novais Cavallone; Walter Belda
Journal:  J Immunol Res       Date:  2021-11-01       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.